Skip to content
lifestyle.socialsinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Candel Therapeutics
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
May 14, 2026
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
May 5, 2026
Candel Therapeutics Announces Proposed $100 Million Public Offering
February 19, 2026
Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
February 19, 2026
Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit
February 12, 2026
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2026
←
Previous Page
1
2
3